Abstract: A process for preparing a nitrated compound, including the step of reacting a compound (A) including at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein the heteroaromatic ring includes at least one heteroatom selected from the group consisting of oxygen, sulfur, phosphor, selenium and nitrogen, with a compound of formula (I) wherein Y is selected from the group consisting of hydrogen and nitro.

Abstract: A method for preparing a biflavone-cobalt complex includes using the amentoflavone as the ligand and the cobalt ion as the central ion, the amentoflavone-cobalt complex is obtained by reaction, and the structure of the complex is characterized by infrared spectroscopy, UV-vis absorption spectroscopy and high resolution mass spectrometry. Meanwhile, the antitumor and antioxidant activities of the amentoflavone-cobalt complex are studied in the present invention. MTT method shows that the amentoflavone-cobalt complex has better antitumor activity, and the antitumor activity thereof is stronger than that of the amentoflavone. Pyrogallol auto-oxidation method, ABTS method and FRAP method show that the antioxidan activity of the amentoflavone-cobalt complex is stronger than that of the amentoflavone itself. The formation of the flavonoid-cobalt complex enhances the antitumor and anti-oxidation activities of the amentoflavone, and is expected to be used in the development of drugs.

Abstract: The invention provides a method of forming an iron hydroxypyrone compound comprising reacting a hydroxypyrone with a non-carboxylate iron salt in an aqueous solution, and precipitating the iron hydroxypyrone compound from the aqueous solution having a pH of greater than 7.

Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.

Abstract: A compound of formula (ascorbate)2Sr:(M+a)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, a composition containing the same, a method of making the same and a method of administering the same as a supplement.

Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.

Abstract: A new radical inhibitor, a composition containing the new radical inhibitor, and a radical generation inhibition method using the new radical inhibitor are provided. A radical inhibitor according to the present invention contains a salen complex compound of a bivalent metal.

Abstract: The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma.

Abstract: Disclosed are a class of platinum compounds with a leaving group of malonic acid derivatives containing amino and alkylamino, their pharmaceutically acceptable salts, their preparation methods and pharmaceutical composites comprising them. Disclosed also are for the uses of the compounds in the treatment of cell proliferative diseases, particularly for the treatment of cancers. The present platinum compounds have high water solubility and low toxicity.

Abstract: An anti-cancer ruthenium complex containing organometallic triruthenium with two maltol ligands is claimed.

Abstract: The invention describes a process for the selective dimerization of ethylene to but-1-ene using a catalytic composition comprising at least one organometallic titanium complex, said organometallic complex containing at least one alkoxy type ligand functionalized by a heteroatom selected from nitrogen, oxygen, phosphorus, sulphur, arsenic and antimony or by an aromatic group.

Abstract: The invention provides a composition comprising at least the following A and B: A) a polymer comprising, in polymerized from, at least one “monomer that comprises at least one hydroxyl group;” and B) an organometal compound comprising at least one metal selected from Ti, Zr, Hf, Co, Mn, Zn, or combinations thereof, and wherein the organometal compound is present in an amount greater than 5 weight percent, based on the sum weight of A and B.

Abstract: The present invention relates to a method for effectively delivering an anticancer drug into cancer cells by binding the anticancer drug to pH-sensitive metal nanoparticles so as to be separated from cancer cells. The pH-sensitive metal nanoparticles according to the present invention may be heated by photothermal therapy, thereby effectively killing cancer cells in conjunction with the isolated anticancer drug.

Abstract: To provide a process for increasing the proportion of an optical isomer of not only a compound having a closed ring but also a compound not having a closed ring when an optical isomer mixture of a compound having both a formyl group and a double bond capable of causing a carbonyl-ene ring closing reaction in the same molecule is subjected to a ring closing reaction. A process for increasing the proportion of an optical isomer characterized by subjecting an optical isomer mixture of a compound having both a formyl group and a double bond capable of causing a carbonyl-ene ring closing reaction in the same molecule to a ring closing reaction in the presence of a predetermined aluminum complex represented by the general formula: [Al2(L1)n(L2)3-n]m.

Abstract: A compound of formula (ascorbate)2Sr:(Ma)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, a composition containing the same, a method of making the same and a method of administering the same as a supplement.

Abstract: A water soluble nanoparticle can include a ligand of formula (I). The ligand can provide zwitterionic character and can provide water solubility, small hydrodynamic diameter, chemical stability, and the capability to modify the nanoparticle with additional functional moieties such as a small molecule, nucleic acid, or protein.

Abstract: The present invention relates to a method for effectively delivering an anticancer drug into cancer cells by binding the anticancer drug to pH-sensitive metal nanoparticles so as to be separated from cancer cells. The pH-sensitive metal nanoparticles according to the present invention may be heated by photothermal therapy, thereby effectively killing cancer cells in conjunction with the isolated anticancer drug.

Abstract: The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma.

Abstract: A compound of formula (ascorbate)2Sr:(M+a)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, a composition containing the same, a method of making the same and a method of administering the same as a supplement.

Abstract: A compound of formula (ascorbate)2Sr:(M+a)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, a composition containing the same, a method of making the same and a method of administering the same as a supplement.

Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.

Abstract: The present invention relates to the preparation of a class of novel, optically active compounds derived from oligomeric proanthocyanidins (OPCs), more particularly to oligomers of epicatechin. These compounds include multidentate ligands and their metal complexes for use in catalysis. Methods of depolymerising proanthocyanidins to form catechins, and particularly depolymerising proanthocyanidins derived from plant sources to form novel epicatechins having application in catalysis are disclosed.

Abstract: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X?, Y, L1?, R1? and R2? are as defined herein, is useful in medical imaging and therapy.

Abstract: The present invention relates to arylated, silylated and/or alkylated bis(2,2?-diphenolato)metallates and to a method for the production thereof.

Abstract: The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitable for therapeutic oral administration.

Abstract: Disclosed are compounds comprising a zinc oxide molecule chemically bound to one or more molecules having an acidic hydrogen, such as an organic acid. The invention also provides compositions comprising such compounds and methods of preparing such compounds. The compounds of the invention may be provided in, for example, topical skin formulations, pharmaceutical compositions, or delivery systems for active ingredients.

Abstract: A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.

Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.

Abstract: A novel compound showing anti-tumor properties was synthesized by reacting Cp2TiCl2 with maltol (3-hydroxy-2-methyl-4-pyrone) and a pH of 5.4, leading to a complete replacement of Cp and chloride ligands affording, Ti(maltolato)2(OH)2. The further crystallization of Ti(maltolato)2(OH)2 at pH of 8.4 leads to the formation of the novel anti-tumor compound [Ti4(maltolato)8(?-O4)].

Abstract: Discussed herein are a charge control agent and toner comprising said charge control agent. Said toner of the invention is comprised of a resin, a colorant, and the charge control agent, wherein, said charge control agent is comprised of a specific type of metal complexes. In the invention, the charge control agent has excellent charge control properties and the characteristics of uniform crystalline size, high charge speed, high thermo stability, low moisture absorption, and good compatibility with resin. The toner of the invention has excellent electrical characteristics and produces stable image of high quality under a wide range of environmental conditions without dusting and fogging.

Abstract: To provide a process for increasing the proportion of an optical isomer of not only a compound having a closed ring but also a compound not having a closed ring when an optical isomer mixture of a compound having both a formyl group and a double bond capable of causing a carbonyl-ene ring closing reaction in the same molecule is subjected to a ring closing reaction. A process for increasing the proportion of an optical isomer characterized by subjecting an optical isomer mixture of a compound having both a formyl group and a double bond capable of causing a carbonyl-ene ring closing reaction in the same molecule to a ring closing reaction in the presence of a predetermined aluminum complex represented by the general formula: [Al1(L1)1(L2)m(Lh)n]k.

Abstract: The invention describes a process for the selective dimerization of ethylene to but-1-ene using a catalytic composition comprising at least one organometallic titanium complex, said organometallic complex containing at least one alkoxy type ligand functionalized by a heteroatom selected from nitrogen, oxygen, phosphorus, sulphur, arsenic and antimony or by an aromatic group.

Abstract: The invention describes a process for oligomerization of olefins into compounds or into a mixture of compounds of general formula CpH2p with 4?p?80 that employs a catalytic composition that comprises at least one organometallic complex of an element of group IV that is selected from among titanium, zirconium, or hafnium, whereby said organometallic complex contains at least one alkoxy-type ligand that is functionalized by a heteroatom that is selected from among nitrogen, oxygen, phosphorus or sulfur, or by an aromatic group.

Abstract: Thioloated taxane derivatives are linked to colloidal metal particles such as gold nanoparticles for use as antitumor agents. The antitumor agents may be targeted to tumors.

Abstract: The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).

Abstract: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X?, Y, L1?, R1? and R2? are as defined herein, is useful in medical imaging and therapy.

Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.

Abstract: Provided are formulations and methods for treating inflammatory bowel disease, including Crohn's disease, ulcerative colitis, and Johne's disease. The formulations provided comprise pharmaceutically acceptable gallium compounds; the methods provided comprise means of using such formulations in the treatment of inflammatory bowel disease and closely related disorders.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: The present invention relates to new tridentate ligand compounds with imino furan units, to a method for manufacturing said compounds and to their use in the preparation of catalysts for the homopolymerisation or copolymerisation of ethylene and alpha-olefins.

Abstract: The present invention discloses metallic complexes based on carbonylamino fulvene ligands; their method of preparation and their use in the oligomerisation or polymerisation of ethylene and alpha-olefins.

Abstract: A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.

Abstract: Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI).

Abstract: A coating liquid including one or more of metal complexes selected from a metal complex A represented by Chemical Formula 1, a metal complex B represented by Chemical Formula 2, and a metal complex C represented by Chemical Formula 3. M in Chemical Formula 1, Chemical Formula 2 and Chemical Formula 3 represents a metal ion. Each of X1-X4 in Chemical Formula 1, Chemical Formula 2 and Chemical Formula 3 is one of O, NH, CO2 and S. Each of Y1-Y8 in Chemical Formula 1 and Y1-Y4 in Chemical Formula 3 is either CH or N. Each of Z1-Z3 in Chemical Formula 2 and Chemical Formula 3 and Z4-Z6 in Chemical Formula 2 is one selected from a group of O, NH and S, and two selected from a group of CH and N. L in Chemical Formula 1, Chemical Formula 2 and Chemical Formula 3 represents an axial ligand. k in Chemical Formula 1, Chemical Formula 2 and Chemical Formula 3 represents a valence of each of the metal complexes and is equal to a sum of electric charges of M, X1-X4 and L.

Abstract: An aluminum chelate-based latent curing agent is provided which can cure a thermosetting epoxy resin at a relatively low temperature in a short period of time. A method for producing such an aluminum chelate-based latent curing agent, whose curing conditions can be relatively easily controlled, is also provided. The aluminum chelate-based latent curing agent is made latent by reacting a silsesquioxane-type oxetane derivative with an aluminum chelating agent in the presence of an alicyclic epoxy compound.

Abstract: A method of forming an iron hydroxypyrone compound comprising reacting an iron salt of a carboxylic acid and a hydroxypyrone in an aqueous solution at a pH greater than 7.

Abstract: Briefly described, embodiments of this disclosure include transition-metal charge-transport materials, methods of forming transition-metal charge-transport materials, and methods of using the transition-metal charge-transport materials.

Abstract: The described invention relates to the new compound “sucrose-octasulphate salified with silver” usefully applicable in the prevention and cure of infections by micro-organisms of bacterial, fungal, viral and/or yeast origins and in the promotion of tissue repair. The silver salts of sucrose octasulphate, subject of the invention have in fact been shown to possess antimicrobial activities even higher than that of known silver compounds. These properties therefore make them particularly suitable for use in different pathological or paraphysiological conditions of the skin, of the epithelia and of the mucosa both intact and lesioned.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: The present invention relates to substituted boron or aluminum spiro compounds and their use in the electronic industry. The compounds of the invention are used as electron transport material, hole blocking material and/or as host material in organic electroluminescence and/or phosphorescence devices, as electron transport material in photocopiers, as electron acceptor or electron transport material in solar cells, as charge transport material in organic ICs (circuits) and in organic solid-state lasers or organic photodetectors.